Recce (ASX:RCE) share price edges lower following study delays

With COVID-19 vaccines front and centre, the delay announced today appears to be giving this pharmaceutical stock the jitters.

| More on:
Two lab technicians carrying out clinical trials

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is falling after the company released an update on its clinical pipeline. In afternoon trade, shares in Recce Pharmaceuticals are trading 0.46% lower at $1.08.

The update announced delays to the company's overseas COVID-19 animal studies.

Let's take a closer at today's news.

Recce's clinical pipeline update

COVID-19 studies

According to Recce, overseas studies testing the efficacy of its RECCE 529 on animals infected with COVID-19 variants has been delayed.

RECCE 529 is a synthetic anti-infective which has, to date, been studied as a treatment for COVID-19.

Some of the studies testing the ability of RECCE 529 to treat COVID-19 variants are experiencing delays, as labs struggle to infect ferrets with the variants.

Despite this, the company believes it will have data on the effectiveness of RECCE 529 against the UK and South African COVID-19 strains by the fourth quarter of 2021.

Meanwhile, Reece's other synthetic anti-infective which has proven to be promising against COVID-19, R327, has shown more encouraging results. It has moved to the second stage of its Australian study, with results due late this year.

Burns trial

Also underway is a human clinical trial using R327 to treat burns. The eight-month trial is being conducted at Fiona Stanley Hospital in Perth, Western Australia.

Recce expects data from the burns trial to be available in the fourth quarter of 2021.

Intravenous trial

R327 is also being injected intravenously in the first phase of a human clinical trial.

According to Recce, so far, injecting R327 intravenously has been found effective in treating sepsis, kidney infections, and urinary tract infections.

The first trial will see healthy patients dosed with R327 in August 2021. Recce expects interim data from the intravenous trial late this year. Full results are likely to be available mid-2022.

Helicobacter pylori pre-clinical studies

Finally, Recce Pharmaceuticals updated the market on its oral compound (RECCE 435) designed to fight helicobacter pylori infections.

The company is currently testing RECCE 435 on mice, and expects results from the pre-clinical study in mid-2022. Recce hopes the results will lead to a clinical study next year.

Recce share price snapshot

The Recce Pharmaceuticals share price has been bobbing along on the ASX so far this year. The most notable peaks were $1.26 and $1.19 in mid-April and early May respectively.

Currently, the Recce Pharmaceuticals share price is up by around 3% year to date. It has gained 32% since this time last year.

The company has a market capitalisation of around $185 million, with approximately 173 million shares outstanding.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

This ASX healthcare stock is up 12% in 2 days since All Ords inclusion: Should you buy?

The latest member of the All Ordinaries index is getting some love this week.

Read more »

two colleagues high five each other as they sit side by side at a long desk in front of their laptop computers in an office environment.
Mergers & Acquisitions

Guess which ASX small cap stock is rocketing 27% on 'transformative' merger

Investors are liking the look of this merger plan.

Read more »

Health professional working on his laptop.
Healthcare Shares

Why Medibank and NIB shares are outperforming today

Premium increases for 2024 have been announced.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Is this a new threat for CSL shares?

There's a new wonder drug on the scene. Should shareholders be concerned?

Read more »

a man in a shirt and tie holds his chin in thoughtful contemplation and looks skywards as if thinking about something while a graphic of a road with many ups and downs unfurls behind him.
Earnings Results

What's with the Neuren Pharmaceuticals share price today?

The full market reaction to the Daybue developer's FY23 earnings report won't be seen until tomorrow.

Read more »

private health insurance diagram.
Healthcare Shares

What's going on with the Medibank share price today?

Shareholders will be happy to see Medibank shares drop in value today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Earnings Results

Mesoblast share price tumbles on US$32.5m half-year loss

This biotech continues to burn cash.

Read more »

Health professional working on his laptop.
Healthcare Shares

Ramsay Health Care share price falls on profit crunch and dividend cut

This private hospital operator continues to battle with higher costs.

Read more »